[go: up one dir, main page]

WO2006043972A8 - Chimeric protein - Google Patents

Chimeric protein

Info

Publication number
WO2006043972A8
WO2006043972A8 PCT/US2005/012194 US2005012194W WO2006043972A8 WO 2006043972 A8 WO2006043972 A8 WO 2006043972A8 US 2005012194 W US2005012194 W US 2005012194W WO 2006043972 A8 WO2006043972 A8 WO 2006043972A8
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
segment
receptor
nucleic acids
rich
Prior art date
Application number
PCT/US2005/012194
Other languages
French (fr)
Other versions
WO2006043972A1 (en
Inventor
Mizhou Hui
Original Assignee
Amprotein Corp
Mizhou Hui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2005296277A priority Critical patent/AU2005296277A1/en
Priority to JP2007536675A priority patent/JP2008515970A/en
Priority to BRPI0516350-1A priority patent/BRPI0516350A/en
Priority to US11/576,963 priority patent/US20080292628A1/en
Priority to MX2007004374A priority patent/MX2007004374A/en
Priority to EP05737667A priority patent/EP1799246A4/en
Application filed by Amprotein Corp, Mizhou Hui filed Critical Amprotein Corp
Priority to NZ554481A priority patent/NZ554481A/en
Priority to CN2005800115254A priority patent/CN101027079B/en
Priority to CA002583937A priority patent/CA2583937A1/en
Publication of WO2006043972A1 publication Critical patent/WO2006043972A1/en
Publication of WO2006043972A8 publication Critical patent/WO2006043972A8/en
Priority to IL182497A priority patent/IL182497A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)

Abstract

A fusion protein containing a first segment that is located at the amino terminus of the fusion protein and specifically binds to and neutralizes a first cytokine or growth factor; and a second segment that is located at the carboxyl terminus of the fusion protein and specifically binds to a second cytokine receptor which is often rich at disease sites such as IL-1 receptor-rich inflammatory site. In addition, the said second segment is usually the receptor antagonist such as IL-1 receptor antagonist and its functional equivalent analogues. Also disclosed are nucleic acids encoding the fusion protein, vectors and host cells having the nucleic acids, and related composition and methods to target inflammatory diseases and indications co-existed with inflammation.
PCT/US2005/012194 2004-10-12 2005-04-08 Chimeric protein WO2006043972A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2007536675A JP2008515970A (en) 2004-10-12 2005-04-08 Chimeric protein
BRPI0516350-1A BRPI0516350A (en) 2004-10-12 2005-04-08 fusion protein, isolated nucleic acid, vector, host cell, method of producing a polypeptide, composition, method of modulating an immunoresponse in an individual, method for increasing the half life of a recombinant protein in an individual, and method for increasing the efficacy of a recombinant protein in an individual and method of applying a therapeutic protein to a target site in an individual
US11/576,963 US20080292628A1 (en) 2004-10-12 2005-04-08 Chimeric Protein
MX2007004374A MX2007004374A (en) 2004-10-12 2005-04-08 Chimeric protein.
EP05737667A EP1799246A4 (en) 2004-10-12 2005-04-08 Chimeric protein
AU2005296277A AU2005296277A1 (en) 2004-10-12 2005-04-08 Chimeric protein
NZ554481A NZ554481A (en) 2004-10-12 2005-04-08 Fusion protein that binds to IL-1 receptor and one of IL18, IL4 or IL13
CN2005800115254A CN101027079B (en) 2004-10-12 2005-04-08 Chimeric protein
CA002583937A CA2583937A1 (en) 2004-10-12 2005-04-08 Chimeric protein
IL182497A IL182497A0 (en) 2004-10-12 2007-04-12 Chimeric protein

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61847604P 2004-10-12 2004-10-12
US60/618,476 2004-10-12
US62899404P 2004-11-17 2004-11-17
US60/628,994 2004-11-17
US65073405P 2005-02-01 2005-02-01

Publications (2)

Publication Number Publication Date
WO2006043972A1 WO2006043972A1 (en) 2006-04-27
WO2006043972A8 true WO2006043972A8 (en) 2006-06-15

Family

ID=39445826

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/012194 WO2006043972A1 (en) 2004-10-12 2005-04-08 Chimeric protein

Country Status (9)

Country Link
EP (1) EP1799246A4 (en)
JP (1) JP2008515970A (en)
KR (1) KR20080022539A (en)
AU (1) AU2005296277A1 (en)
BR (1) BRPI0516350A (en)
CA (1) CA2583937A1 (en)
IL (1) IL182497A0 (en)
NZ (1) NZ554481A (en)
WO (1) WO2006043972A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
EP4269443A3 (en) * 2007-12-26 2023-12-27 Xencor, Inc. Fc variants with altered binding to fcrn
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
EP2620139B1 (en) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1 receptor antagonist rich solutions
WO2009149205A2 (en) * 2008-06-03 2009-12-10 Neurotech Usa, Inc. Cell lines that secrete soluble vegf receptors and uses thereof
EA201170031A1 (en) * 2008-07-02 2011-08-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс BINDING MULTIPLE TARGETS PROTEINS WITH ANTAGONISTIC ACTION TGF-β
KR20110044991A (en) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 TNP-α antagonist multi-target binding protein
AU2010236256C1 (en) 2009-04-16 2015-10-22 Abbvie Biotherapeutics Inc. Anti-TNF-alpha antibodies and their uses
AU2010262836B2 (en) 2009-06-17 2015-05-28 Abbvie Biotherapeutics Inc. Anti-VEGF antibodies and their uses
AU2010292486B2 (en) 2009-08-27 2014-08-07 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
KR101004363B1 (en) * 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 TNF-α AND IL-21 COUPLED ANTAGONIST FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES
KR101004362B1 (en) * 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 NTF-α and TVE double antagonists for the prevention and treatment of autoimmune diseases
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9878011B2 (en) * 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9833474B2 (en) 2013-11-26 2017-12-05 Biomet Biologies, LLC Methods of mediating macrophage phenotypes
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
US20240018206A1 (en) 2020-05-25 2024-01-18 Beijing Vdjbio Co., Ltd. An interleukin-1 receptor antagonist and a fusion protein containing the same
CN113402583B (en) * 2021-06-19 2023-03-21 江西农业大学 QGK tripeptide and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
SG47099A1 (en) * 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
EP1781684A4 (en) * 2004-08-25 2008-05-21 Amprotein Corp A novel chimeric polypeptide and use thereof

Also Published As

Publication number Publication date
BRPI0516350A (en) 2008-09-02
NZ554481A (en) 2010-04-30
AU2005296277A1 (en) 2006-04-27
KR20080022539A (en) 2008-03-11
EP1799246A1 (en) 2007-06-27
JP2008515970A (en) 2008-05-15
CA2583937A1 (en) 2006-04-27
IL182497A0 (en) 2007-09-20
EP1799246A4 (en) 2009-08-12
WO2006043972A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
WO2006043972A8 (en) Chimeric protein
AR128541A2 (en) METHODS TO MODIFY THE ISOELECTRIC POINT OF ANTIBODIES BY SUBSTITUTING AMINO ACIDS IN THE COMPLEMENTARITY DETERMINATION REGION (CDR)
WO2004039951A3 (en) Il-1 receptor based antagonists and methods of making and using
WO2008079290A3 (en) Stable buffered formulations containing polypeptides
WO2007130302A3 (en) Rage fusion proteins, formulations, and methods of use thereof
WO2006038027A3 (en) SINGLE DOMAIN ANTIBODIES AGAINST TNFRl AND METHODS OF USE THEREFOR
WO2005052000A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
WO2006105152A3 (en) Amnion-derived cell compositions, methods of making and uses thereof
EP2526968A3 (en) Nogo receptor antagonists
WO2006033700A3 (en) Her2 antibody composition
WO2008028977A3 (en) Serum albumin binding proteins with long half-lives
RU2010116152A (en) ANTIBODY AGAINST IL-6 RECEPTOR
WO2007027713A3 (en) Trail receptor 2 polypeptides and antibodies
WO2006023491A3 (en) Method of delivering rna interference and uses thereof
WO2008067223A3 (en) Il-17a/f heterodimeric polypeptides and therapeutic uses thereof
WO2004085476A3 (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation
IS7677A (en) Antagonist Nogo receptors
IL179211A0 (en) Site specific incorporation of heavy atom-containing unnatural amino acids into proteins for crystal structure determination
IS8339A (en) Anti-NOGO receptor antagonists
WO2008049070A3 (en) Il-17c antagonists and methods of using the same
WO2007094926A3 (en) Rage fusion proteins and methods of use
WO2006086396A3 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2008035217A3 (en) Fusion proteins comprising two or more igg binding domains of streptococcal protein g.
WO2005021578A3 (en) A novel chimeric polypeptide and use thereof
WO2008010096A3 (en) Method for preparing recombinant mycobacterial polypeptides in yeast and their use in diagnosis of mycobacterial related diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 17/2006 UNDER (30) ADD "NOT FURNISHED, 1 FEBRUARY 2005 (01.02.2005), US"

WWE Wipo information: entry into national phase

Ref document number: 200580011525.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 509/MUMNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007536675

Country of ref document: JP

Ref document number: 554481

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/004374

Country of ref document: MX

Ref document number: 2005296277

Country of ref document: AU

Ref document number: 2005737667

Country of ref document: EP

Ref document number: 2583937

Country of ref document: CA

Ref document number: 182497

Country of ref document: IL

Ref document number: 1020077008321

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007117716

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005737667

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11576963

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0516350

Country of ref document: BR